Mihir Jain: Can Gene Therapy Transform Hemophilia Care in India?
Mihir Jain, MBBS graduate from Government Medical College and Hospital (GMCH), Chandigarh, shared a post on LinkedIn:
“Can gene therapy transform hemophilia care in India?
I recently completed an independent healthcare strategy project exploring the commercial and market access landscape for hemophilia gene therapy in India.
The project combines my medical background with data-driven analysis to evaluate:
- Market opportunity
- Patient population and treatment landscape
- Access and reimbursement challenges
- Competitive environment
- Strategic considerations for commercialization
The project includes:
As an MBBS graduate, I’m building a portfolio at the intersection of healthcare consulting, life sciences strategy, medical affairs, pharmacovigilance, and data analytics by tackling real-world industry questions.
I welcome feedback and would be glad to connect with professionals working in healthcare consulting, pharma, biotech, and life sciences.”
Stay updated with Hemostasis Today.
-
Oct 19, 2026, 06:02Thomas Dayspring: Vascular Resilience – What Is It and How Can We Measure It?
-
Oct 19, 2026, 05:53Kevon Dindial: Collaboration for Better Childhood Cancer Outcomes
-
Oct 19, 2026, 05:44Mavis Agnes Kisakye: Raising Awareness about Haemophilia and Other Blood Disorders at Luweero General Hospital
-
Oct 19, 2026, 05:43Mohsen Asadi: Women and Blood Clots – Understanding Risk Across Every Life Stage
-
Oct 19, 2026, 05:39Shivir Moosai: Warm AIHA in a Young Woman
-
Oct 19, 2026, 03:54Jennifer Trowbridge: How Mutant Blood Stem Cells Use Inflammation to Drive Their Own Expansion
-
Oct 19, 2026, 03:39Wyenona Hicks: Catching Up With Old Friends and New Colleagues at AABB 2026
-
Oct 19, 2026, 03:33Developing a Non-Invasive Treatment for Life-Threatening PE – University of Michigan College of Engineering
-
Oct 19, 2026, 03:28Jim Hoffman: How NETs Contribute to Gallstone Formation and Growth